Stoke Therapeutics
STOK
151 hedge funds and large institutions have $1.57B invested in Stoke Therapeutics in 2025 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 46 increasing their positions, 42 reducing their positions, and 20 closing their positions.
448% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $2.44M
112% more capital invested
Capital invested by funds: $744M → $1.57B (+$830M)
90% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 20
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more funds holding
Funds holding: 133 → 151 (+18)
3.47% more ownership
Funds ownership: 120.06% → 123.53% (+3.5%)
10% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$28.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.4M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$13.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.3M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$7.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$26.3M |
| 2 |
ST
Skorpios Trust
Limassol,
Cyprus
|
-$17.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.39M |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$7.49M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$5.69M |
STOK Hedge Fund Activity: Q3 2025 in Review
151 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2025, worth a combined $1.57B — up 112% from $744M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new STOK positions and 20 closed out — a net gain of 18 holders — while 46 added to existing stakes and 42 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $28.4M. The largest seller was Marshall Wace, cutting an estimated $26.3M.
- 151 institutional investors held Stoke Therapeutics (STOK) as of Q3 2025, up from 133 in Q2 2025.
- Funds reported $1.57B of Stoke Therapeutics stock for Q3 2025, up 112% quarter-over-quarter.
- 38 funds opened new Stoke Therapeutics positions in Q3 2025 and 20 closed out, a net change of +18 holders.
- The largest Stoke Therapeutics buyer in Q3 2025 was BVF Inc, an estimated $28.4M added.
- The largest Stoke Therapeutics seller in Q3 2025 was Marshall Wace, an estimated $26.3M sold.
Based on aggregated 13F filings for Q3 2025.